Biochips Market

The biochips market is projected to reach USD 21.36 billion by 2030 from USD 14.01 billion in 2025, growing at a CAGR of 8.8% during the forecast period.

The growth of the global biochips market can largely be attributed to the increasing demand for personalized medicine and the rising focus on precision diagnostics. The growing prevalence of chronic and infectious diseases, alongside the expanding applications in drug discovery, genomics, and proteomics, is driving the widespread adoption of biochip technology. Additionally, the increasing emphasis on non-invasive diagnostic techniques, such as liquid biopsy, and the growing need for high-throughput screening in both clinical and research settings are contributing to market expansion. The integration of advanced technologies, including AI, machine learning, and microfluidics, is further fueling product innovation and efficiency in biochip applications. Moreover, the rising demand for point-of-care diagnostics, the expansion of research collaborations between academia and industry, and the increasing penetration of e-commerce distribution channels are enhancing accessibility and adoption, particularly in emerging markets.

The prominent players in the biochips market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), among others. These companies have implemented a variety of growth strategies, both organic and inorganic, including the introduction of new products, the formation of strategic partnerships, and penetration into emerging markets. These initiatives are aimed at enhancing their market share and diversifying their portfolios.

To know about the assumptions considered for the study download the pdf brochure

In November 2024, QIAGEN (Germany) announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen its business. The new site, set to open in early 2026, will encompass the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the causes of illnesses, particularly in respiratory, gastrointestinal, and meningitis/encephalitis conditions.

In April 2024, Illumina, Inc. (US) announced that DRAGEN Array, a bioinformatics software suite for analysis of Infinium microarray data, enhanced its functionality by enabling high-throughput and quantitative reporting of quality control (QC) metrics for Infinium methylation arrays.

Thermo Fisher Scientific Inc. is a global provider of scientific instrumentation, reagents, consumables, and software & services across healthcare, life sciences, academia, government, and biotechnology sectors. Its offerings include life sciences tools, analytical instruments, specialty diagnostics, and laboratory/biopharma services, such as supply chain, clinical trial services, and contract development & manufacturing. Operating through brands like Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD, the company is structured into four segments: Life Sciences Solutions, Laboratory Products & Biopharma Services, Analytical Instruments, and Specialty Diagnostics. The Life Sciences Solutions segment provides reagents, instruments, consumables, and services for research, diagnostics, and vaccine/drug production, while the other segments offer instruments, consumables, and services for applications in research, development, and clinical diagnostics. Thermo Fisher serves over 400,000 customers globally, supported by a team of 15,000+ sales personnel, and operates in over 100 countries.

Illumina, Inc. is a leading genomics and life sciences company that designs, manufactures, and markets integrated systems for analyzing genetic variation and biological function. Its product portfolio includes next-generation sequencing instruments, array-based genotyping systems, library preparation kits, sequencing reagents, consumables, and software/analytics solutions. Its technologies enable research in fields such as oncology, reproductive health, infectious disease, agriculture, and population genomics, supporting customers in academic, clinical, government, and commercial sectors. The company operates under a single business segment, Core Illumina, which encompasses its sequencing and array systems, consumables, services, and informatics. Following the spin-off of GRAIL, a cancer early-detection diagnostics business, in mid-2024, Illumina reports solely through Core Illumina. The company serves customers in over 165 countries, with subsidiaries supporting regional sales, manufacturing, R&D, and customer service in markets including Germany, India, China, and France.

Market Ranking

The top five companies of the biochips market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), and QIAGEN (Germany). Thermo Fisher Scientific Inc. (US) is advancing its position in the biochips market by enhancing its microarray technologies and bioinformatics solutions, supporting applications in genomics, diagnostics, and drug discovery. Illumina, Inc. (US) continues to lead in genetic analysis with its microarray technologies and genotyping systems, driving innovation in genomic research and personalized medicine. Agilent Technologies, Inc. (US) is expanding its offerings in genomic profiling and molecular diagnostics, with a focus on cancer diagnostics and precision medicine through its advanced analytical tools. F. Hoffmann-La Roche Ltd (Switzerland) is strengthening its portfolio in molecular diagnostics, focusing on oncology and genetic testing technologies to support personalized healthcare. QIAGEN (Germany) focuses on molecular testing and genetic analysis to advance precision medicine and oncology diagnostics.

Related Reports:

Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com